Integral Diagnostics Ltd (ASX: IDX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Integral Diagnostics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Integral Diagnostics Ltd (ASX: IDX)
Latest News
Broker Notes
2 ASX shares to buy now at bargain prices that you've forgotten about
52-Week Lows
Is opportunity knocking? 2 ASX All Ordinaries shares hitting 52-week lows
Earnings Results
Integral Diagnostics (ASX:IDX) share price on ice after trio of big announcements
Ask a Fund Manager
2 ASX shares to buy for dirt cheap right now: expert
Broker Notes
Here are the latest broker updates from Macquarie. It's not all pretty for ASX shares.
Broker Notes
Top brokers name 3 ASX shares to buy next week
Share Fallers
Why Integral Diagnostics, Mayne Pharma, NEXTDC, & Wesfarmers are dropping
Earnings Results
Integral Diagnostics (ASX:IDX) share price slides 14% on FY21 earnings
Share Market News
Which ASX shares are ending the week as the biggest movers today?
Share Fallers
Why Chalice Mining, GUD, Integral Diagnostics, & PointsBet are dropping
Dividend Investing
2 growing ASX dividend shares analysts rate as buys
Share Market News
2 All Ords shares this broker rates as buys
Frequently Asked Questions
-
Yes, Integral Diagnostics historically pays two fully franked dividends a year.
-
Integral Diagnostics generally pays its shareholder dividends in April and October.
-
Integral Diagnostics Ltd listed on the ASX on 21 October 2015.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 29 Aug 2025 | $0.0400 | 100.00% | Final | 03 Oct 2025 |
| 06 Mar 2025 | $0.0250 | 100.00% | Interim | 07 Apr 2025 |
| 30 Aug 2024 | $0.0330 | 100.00% | Final | 03 Oct 2024 |
| 29 Feb 2024 | $0.0250 | 100.00% | Interim | 02 Apr 2024 |
| 31 Aug 2023 | $0.0350 | 100.00% | Final | 04 Oct 2023 |
| 02 Mar 2023 | $0.0250 | 100.00% | Interim | 04 Apr 2023 |
| 01 Sep 2022 | $0.0300 | 100.00% | Final | 05 Oct 2022 |
| 01 Mar 2022 | $0.0400 | 100.00% | Interim | 04 Apr 2022 |
| 02 Sep 2021 | $0.0700 | 100.00% | Final | 06 Oct 2021 |
| 01 Mar 2021 | $0.0550 | 100.00% | Interim | 06 Apr 2021 |
| 28 Aug 2020 | $0.0400 | 100.00% | Final | 01 Oct 2020 |
| 28 Feb 2020 | $0.0550 | 100.00% | Interim | 07 Apr 2020 |
| 30 Aug 2019 | $0.0500 | 100.00% | Final | 02 Oct 2019 |
| 01 Mar 2019 | $0.0500 | 100.00% | Interim | 02 Apr 2019 |
| 31 Aug 2018 | $0.0400 | 100.00% | Final | 04 Oct 2018 |
| 31 Jan 2018 | $0.0400 | 100.00% | Interim | 05 Mar 2018 |
| 31 Aug 2017 | $0.0000 | 100.00% | Final | 04 Oct 2017 |
| 28 Feb 2017 | $0.0300 | 100.00% | Interim | 30 Mar 2017 |
| 31 Aug 2016 | $0.0400 | 100.00% | Final | 04 Oct 2016 |
IDX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Integral Diagnostics Ltd
Integral Diagnostics Ltd (ASX: IDX) is an Australian healthcare services company providing medical imaging services.
The group operates in a single business providing diagnostic imaging to general practitioners, medical specialists, and allied health professionals and their patients.
The company operates more than 90 radiology clinics across Australia and New Zealand. It is also a joint venture partner in Medx, expanding its services to the United Kingdom and Ireland.
IDX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Jan 2026 | $2.64 | $0.04 | 1.54% | 339,743 | $2.57 | $2.64 | $2.57 |
| 12 Jan 2026 | $2.60 | $0.06 | 2.36% | 345,855 | $2.53 | $2.60 | $2.52 |
| 09 Jan 2026 | $2.54 | $-0.01 | -0.39% | 492,111 | $2.53 | $2.57 | $2.52 |
| 08 Jan 2026 | $2.55 | $0.04 | 1.59% | 424,631 | $2.50 | $2.56 | $2.48 |
| 07 Jan 2026 | $2.51 | $0.00 | 0.00% | 491,913 | $2.52 | $2.52 | $2.49 |
| 06 Jan 2026 | $2.51 | $-0.02 | -0.79% | 573,933 | $2.58 | $2.58 | $2.49 |
| 05 Jan 2026 | $2.53 | $0.02 | 0.80% | 387,652 | $2.52 | $2.57 | $2.52 |
| 02 Jan 2026 | $2.51 | $-0.03 | -1.18% | 245,418 | $2.52 | $2.55 | $2.51 |
| 31 Dec 2025 | $2.54 | $0.08 | 3.25% | 553,641 | $2.47 | $2.55 | $2.47 |
| 30 Dec 2025 | $2.46 | $0.04 | 1.65% | 844,043 | $2.42 | $2.48 | $2.42 |
| 29 Dec 2025 | $2.42 | $-0.03 | -1.22% | 436,763 | $2.45 | $2.46 | $2.42 |
| 24 Dec 2025 | $2.45 | $-0.03 | -1.21% | 259,506 | $2.48 | $2.48 | $2.42 |
| 23 Dec 2025 | $2.48 | $0.06 | 2.48% | 763,395 | $2.46 | $2.49 | $2.40 |
| 22 Dec 2025 | $2.42 | $0.01 | 0.41% | 598,867 | $2.46 | $2.46 | $2.40 |
| 19 Dec 2025 | $2.41 | $0.00 | 0.00% | 913,323 | $2.40 | $2.43 | $2.38 |
| 18 Dec 2025 | $2.41 | $-0.05 | -2.03% | 3,036,855 | $2.53 | $2.53 | $2.30 |
| 17 Dec 2025 | $2.46 | $-0.02 | -0.81% | 551,328 | $2.47 | $2.49 | $2.46 |
| 16 Dec 2025 | $2.48 | $0.02 | 0.81% | 641,547 | $2.47 | $2.49 | $2.45 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 31 Dec 2025 | James Hall | Buy | 6,200 | $15,066 |
On-market trade.
|
| 22 Dec 2025 | Ian Kadish | Buy | 34,233 | $82,843 |
Conversion of securities.
|
| 22 Dec 2025 | Ian Kadish | Exercise | 34,233 | $82,843 |
Conversion of securities. 7,77,919 rights
|
| 16 Dec 2025 | Ian Kadish | Issued | 235,596 | $584,278 |
Issue of securities. 812,132 Rights
|
| 03 Oct 2025 | James Hall | Issued | 2,652 | $7,666 |
Dividend Reinvestment Plan (DRP).
|
| 29 Aug 2025 | Ian Kadish | Exercise | 29,072 | $84,599 |
Conversion of securities. 576,536 Rights
|
| 29 Aug 2025 | Ian Kadish | Issued | 29,072 | $84,599 |
Conversion of securities.
|
| 28 Aug 2025 | Ian Kadish | Expiry | 398,962 | $1,172,948 |
As advised by the company. Lapse of rights. 605,608 rights
|
| 07 Apr 2025 | James Hall | Issued | 2,088 | $4,738 |
Dividend Reinvestment Plan (DRP).
|
| 11 Mar 2025 | Raelene Murphy | Buy | 15,000 | $35,400 |
On-market trade.
|
| 05 Mar 2025 | Ian Kadish | Buy | 25,000 | $53,950 |
On-market trade.
|
| 04 Mar 2025 | James Hall | Buy | 36,000 | $78,840 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Andrew James Fay | Non-Executive Director | Jul 2022 |
Mr Fay brings to the Board over 30 years of experience in funds and investment management, including Chief Executive Officer and Chief Investment Officer roles at Deutsche Asset Management (Australia) Limited. He also held a number of other senior investment roles at Deutsche Asset Management and previously at AMP Capital. He was a member of the Investment Board Committee of the Financial Services Council. Andrew is an experienced company director across ASX-listed, private and regulated entities and accordingly brings to the Board skills in financial and risk management, capital markets, executive remuneration frameworks, strategy, investment and corporate governance. Specifically, he has sector experience and expertise in financial services, including investment, funds, property and infrastructure management. He is Chair of the People, Culture Committee.
|
| Ms Raelene Margaret Murphy | Non-Executive Director | Oct 2017 |
Ms Murphy, beginning her career in audit, has over 30 years of experience in strategic, financial and operational leadership in both industry and professional advisory. She was formerly a Partner in a national accounting firm, Managing Director of Korda Mentha and CEO of the Delta Group. In her professional advisory career, she specialised in operational and financial restructuring, with a particular emphasis on merger and acquisition integration across a range of significant public and private companies. She is Member of the Risk, Compliance and Sustainability Committee and Member of the People, Culture Committee.
|
| Ms Ingrid Anne Player | Non-Executive Director | Aug 2023 |
Ms Player is an experienced former Executive and Non Executive Director with international commercial and regulatory experience in mergers and acquisitions, corporate governance, capital developments, risk and sustainability that spans different markets and industries in Australia and Europe. Her experience includes her senior executive roles with one of Australias leading healthcare providers, where she worked closely with the Board to deliver various capital raisings, retail listed notes, and debt finance deals. Her roles included Group Executive for Legal, Governance and Sustainability as well as General Counsel and Company Secretary. She is Chair of the Risk, Compliance and Sustainability Committee and Member of the People, Culture Committee.
|
| Mr James Tobias Hall | Non-Executive DirectorNon-Executive Chairman | Sep 2023 |
Mr Hall healthcare executive leadership experience in Australia and New Zealand and is an experienced Board and Committee Chair. He was the Group CEO of St Vincents Health Australia, the second largest non government provider of hospital and care services in the country. He has also overseen multi site, for profit generating businesses at both board and executive levels in employment services, early learning services and aged care. He also has involvement in policy development at a federal level in Australia, having served on committees established by Prime Ministers, Deputy Prime Ministers, Health Ministers, Employment and Social Services Ministers. He is currently Non Executive Chair of For Purpose Aged Care, Non Executive Director of UNICEF Australia, a Director of Papua New Guinea Sustainable Development Fund and a trustee of Yajilarra. He is Member of the People, Culture Committee.
|
| Dr Ian Kadish | Chief Executive OfficerManaging Director | May 2017 |
Dr Kadish began his career as a medical doctor in Johannesburg, South Africa. He followed with several roles overseas including McKinsey and Company, CSC Healthcare in New York City, and Netcare, a major hospital group in South Africa and the United Kingdom, where he was an Executive Director. His roles have included CEO and MD of Healthcare Australia, CEO and MD of Pulse Health Group and CEO of Laverty Pathology. He is Director of the Australian Diagnostic Imaging Association (ADIA). He is Member of the Integral Clinical Leadership Committee.
|
| Ms Laura Nicole McBain | Non-Executive Director | Dec 2024 |
Ms McBain had been a Non Executive Director of Capitol. She is an experienced Executive and Non Executive Director with a strong background in the food, beverage, and consumer industries, specialising in brand development, fast growth, corporate governance, financial oversight, and business development. Her experience includes senior leadership roles as Managing Director at Bellamys Australia Limited and Maggie Beer Holdings Limited. She currently serves as a Non Executive Director at Tasmanian Irrigation Pty Ltd and the Tasmanian Devils AFL Club and is also a Director of the Australia China Business Council and President of its Tasmania Branch. In recognition of her leadership and contributions, she was named the 2013 Telstra Tasmanian Businesswoman of the Year and the Telstra Australian Businesswoman of the Year. She is Member of the Risk, Compliance and Sustainability Committee.
|
| Dr Kevin (Kai-Chung) Shaw | Non-Executive Director | Dec 2024 |
Dr Shaw had been a Non Executive Director of Capitol. He has sub specialty training in neuroradiology and musculoskeletal imaging. He is the current Director of Medical Imaging at Barwon Health. He is also a Clinical Professor at Deakin Medical School. He is a past examiner for the Royal Australian and New Zealand College of Radiologists (RANZCR) and previously sat on the Colleges Anatomy Exam Review Panel. He has been an MRI Clinical Reviewer for the College since 2014. Kevin currently sits on the Medical Advisory Committee, Technology/Clinical Practice Committee, and Mortality Committee at Barwon Health, as well as the Medical Imaging Advisory Board at Deakin University. He is a councilor for Australian Medical Association Victoria as the State Representative for RANZCR. He is Member of the Risk, Compliance and Sustainability Committee and Member of the People, Culture Committee.
|
| Mr Manish Mittal | Non-Executive Director | Feb 2025 |
Dr Mittal has a professional focus on MRI, including musculoskeletal, prostrate and cardiac imaging in addition to experience in neuroradiology and abdominal radiology. He also has experience in hospital settings including emergencies and trauma. He has held teaching roles at Melbourne University & Deakin University. He has worked within IDX and its precursor businesses for over 18 years and held senior clinical governance and leadership roles across a number of IDX business units which have enabled him to develop a deep understanding of the IDX operating businesses. He is Member of the Risk, Compliance and Sustainability Committee.
|
| Mr John J Merity | Company Secretary | Jun 2024 |
-
|
| Craig White | Chief Financial Officer |
-
|
|
| John J Merity | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 76,697,943 | 20.59% |
| Citicorp Nominees Pty Limited | 70,835,402 | 19.02% |
| J P Morgan Nominees Australia Pty Limited | 64,194,143 | 17.24% |
| Washington H Soul Pattinson and Company Limited | 10,632,490 | 2.85% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/c> | 9,070,392 | 2.44% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 6,499,188 | 1.75% |
| BNP Paribas Nominees Pty Ltd <HUB24 Custodial Serv Ltd> | 5,869,917 | 1.58% |
| UBS Nominees Pty Ltd | 5,066,697 | 1.36% |
| HSBC Custody Nominees (Australia) Limited <NT Comnwlth Super Corp A/c> | 3,688,396 | 0.99% |
| Kim New Holdings Pty Ltd | 3,389,045 | 0.91% |
| BNP Paribas Noms (NZ) Ltd | 3,131,792 | 0.84% |
| Lethean Holdings Pty Ltd <Howitt No 8 A/c> | 2,944,760 | 0.79% |
| Idinoc Pty Ltd <J & R Conidi Family A/c> | 2,502,713 | 0.67% |
| Firbar Pty Ltd <The Howitt No 4 A/c> | 2,357,230 | 0.63% |
| J A Mullins Pty Ltd <James Mullins Family A/c> | 2,316,051 | 0.62% |
| Masfen Securities Limited | 2,250,000 | 0.60% |
| Mittal Holdings Pty Ltd <Howitt No 12 A/c> | 2,085,907 | 0.56% |
| A & S French Pty Ltd <The A J French Family A/c> | 1,797,915 | 0.48% |
| Wyndham Salter Pty Ltd <The Howitt No 10 A/c> | 1,792,947 | 0.48% |
| BNP Paribas Noms Pty Ltd | 1,622,012 | 0.44% |